retatrutide gip glp-1 glucagon receptor agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Use of an unapproved triple-hormone

Tirzepatide (dual GLP-1/GIP receptor agonist): In the SURMOUNT-1 trial, participants on the highest tirzepatide dose (15 mg) achieved approximately 22.5% body weight reduction at 72 weeks

First, it is a once-a-week injection, whereas liraglutide is once daily, so this may be more tolerable and less time-consuming for participants

Anyone participating in a clinical trial who experiences persistent or severe gastrointestinal symptoms, unexplained abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of dehydration, or other concerning symptoms should contact their supervising healthcare team promptly

If you are fewer than eight weeks into treatment and have not yet reached at least 4 mg, you are in the adjustment phase

To verify that the pharmacy or state-licensed telehealth is legitimate, you can do that via the NABP Safe Pharmacy

Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes